Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia

Stephane De Botton, Thomas Cluzeau, MDPhD, Carlos Enrique Vigil, MD, Rachel J. Cook, MD, Philippe Rousselot, MDPhD, David A Rizzieri, MD, Jane L. Liesveld, MD, Pierre Fenaux, MD PhD, Thorsten Braun, MD PhD, Anne Banos, MD, Michael R. Savona, MD, Don Park, MD, Michael J. Kelly, MD MPH, MS, Angela Volkert, Li Zhou, PhD, Qing Kang-Fortner, PhD, David A. Roth, MD, Eytan M. Stein, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-134600

Published: 2020

Journal Articles

Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

Eytan M. Stein, MD, Stephane De Botton, Thomas Cluzeau, MDPhD, Arnaud Pigneux, MD PhD, Jane L. Liesveld, MD, Rachel J. Cook, MD, Philippe Rousselot, MDPhD, David A Rizzieri, MD, Thorsten Braun, MD PhD, Dale L. Bixby, MD, Gail J. Roboz, MD, Delphine Lebon, MD, Mael Heiblig, Michael J. Kelly, MD MPH, MS, Angela Volkert, Li Zhou, PhD, Qing Kang-Fortner, PhD, David A. Roth, MD, Pierre Peterlin, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-134602

Published: 2020

Journal Articles

Early Completion of Medical Orders for Life-Sustaining Treatment (MOLST) and Hospice Enrollment Are Associated with Improved End of Life (EOL) Quality Metrics in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Marissa Locastro, BS, Kah Poh Loh, MBBCHBAO, Andrea M. Baran, MS, Jane L. Liesveld, MD, Michael W. Becker, MD, Kristen Marie O'Dwyer, MD, Eric Huselton, MD, Omar S. Aljitawi, MD, Megan Baumgart, MD, Eric Snyder, Benzi Kluger, MD, Jason H. Mendler, MD PhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-139475

Published: 2020

Journal Articles

Treatment Decision-Making and Decisional Support Experiences Among Acute Myeloid Leukemia Survivors

Elissa C. Kranzler, PhD, Erica E. Fortune, PhD, Melissa F. Miller, PhD MPH, Kelly Clark, MA, Jemeille Ackourey, MPH, Linda Bohannon, RN, BSN, MSM, Heather Badt, MBA, LSS, Thomas W. Leblanc, Jane L. Liesveld, MD, Kristin Scheeler, MS, Alexandra K Zaleta, PhD

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-136747

Published: 2020

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Older Adults with Acute Myeloid Leukemia (AML)

Jodi J Lipof, MD, Dharmini Manogna, MD, Andrea M. Baran, MS, Bassil Said, MD, Michael W. Becker, MD, Jason H. Mendler, MD PhD, Omar S. Aljitawi, MD, Kristen Marie O'Dwyer, MD, Eric Huselton, MD, Richard Burack, MD PhD, Margaret Blaney, Taylor Douglas, Jane L. Liesveld, MD, Kah Poh Loh, MBBCHBAO

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-136739

Published: 2020

Journal Articles

A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Paul M. Barr, MD, Shuo Ma, MD PhD, Clive S. Zent, MD, Andrea M. Baran, MS, Andrew Bui, Philip J Meacham, PhD, Ashley Morrison, RN, Kelsey Holkovic, RN, Jane L. Liesveld, MD, Deborah A Mulford, MD, Peter Sportelli, BS, Hari P. Miskin, MSc, Michael S. Weiss, Jonathan W. Friedberg, MD MSSc, Brian T. Hill, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-134818

Published: 2020

Journal Articles

A Specific Mesenchymal Stem and Progenitor Cell (MSPC) Subpopulation with a Multi-Potent Gene Signature Is Transcriptionally Altered in the Setting of Myelodysplastic Syndrome (MDS) in Primary Human Bone Marrow Aspirates

Thomas J Fountaine, MD, Mark W LaMere, BA, Daniel K Byun, BS, Jason R Myers, MS, John M Ashton, PhD, Jane L. Liesveld, MD, Youmna Kfoury, PhD, David T. Scadden, MD, Michael W. Becker, MD, Laura M. Calvi, MD

Blood (2019) 134 (Supplement_1): 1708.

https://doi.org/10.1182/blood-2019-130227

Published: 2019

Journal Articles

High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

Daniel J. DeAngelo, MD PhD, Brian A Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, MD, Anjali S. Advani, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Michael E O'Dwyer, MD, William E. Fogler, PhD, John L. Magnani, PhD, Mary M Chen, MD PhD, Eric J. Feldman, MD, Helen M Thackray, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2690.

https://doi.org/10.1182/blood-2019-123744

Published: 2019

Journal Articles

A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Paul M. Barr, MD, Brian T. Hill, MD, Shuo Ma, MD PhD, Andrea M Baran, MS, Andrew Bui, Philip J Meacham, MS, Ashley Morrison, Jane L. Liesveld, MD, Deborah A Mulford, MD, Peter Sportelli, BS, Hari P Miskin, MSc, Michael S Weiss, Jonathan W. Friedberg, MD, Clive S Zent, MD

Blood (2019) 134 (Supplement_1): 360.

https://doi.org/10.1182/blood-2019-123404

Published: 2019

Journal Articles

Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide

Luke Eastburg, MD, David A. Russler-Germain, MDPhDBS, Ramzi Abboud, MD, Peter Westervelt, MD PhD, John F. DiPersio, MD PhD, Michael W. Becker, MD, Neha Kumar, MD, Omar S. Aljitawi, MD, Jeffrey R. Andolina, MD MS, Thomas J Fountaine, MD, Jane L. Liesveld, MD, Eric Huselton, MD

Blood (2019) 134 (Supplement_1): 4496.

https://doi.org/10.1182/blood-2019-129872

Published: 2019

Journal Articles

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Daniel J. DeAngelo, MD PhD, Harry P. Erba, MD PhD, Brian A Jonas, MD PhD, Michael E O'Dwyer, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Gerwin Huls, MD PhD, Jane L. Liesveld, MD, Brenda Cooper, MD, Bhavana Bhatnagar, DO, Geoffrey L. Uy, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Michael B. Armstrong, MD PhD, William E. Fogler, PhD, Mary M Chen, MD PhD, John L. Magnani, PhD, Helen M Thackray, MD, Eric J. Feldman, MD, Anjali S. Advani, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2650.

https://doi.org/10.1182/blood-2019-123816

Published: 2019

Journal Articles

Alliance A041701 - a Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia (AML) Receiving Intensive Induction Chemotherapy

Geoffrey L. Uy, MD, Jun Yin, PhD, Heidi D. Klepin, MD, Shira Dinner, MD, Anthony J. Jaslowski, MD, Stephen A. Strickland, MD, Jane L. Liesveld, MD, John C. Byrd, MD, Richard M. Stone, MD

Blood (2019) 134 (Supplement_1): 1366.

https://doi.org/10.1182/blood-2019-127142

Published: 2019

Journal Articles

Cancer-Related Distress and Unmet Needs Among Acute Myeloid Leukemia Survivors

Alexandra K Zaleta, PhD, Pierre Gardan, Shauna McManus, BS, Melissa F. Miller, PhD MPH, Kelly Clark, MA, Nicole E Nicksic, PhD MPH, Hildy Dillon, MPH, Tara Albrecht, PhDANP, Areej El-Jawahri, MD, Clare Karten, MS, Thomas W. LeBlanc, MDMA,MHS, Jane L. Liesveld, MD, Elizabeth Muenks, PhD, Barbara B. Rogers, CRNP, MN, AOCN, ANP-BC, Kristin Scheeler, MS, Linda House, RN, BSN, MSM

Blood (2019) 134 (Supplement_1): 4787.

https://doi.org/10.1182/blood-2019-123456

Published: 2019

Journal Articles

Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses

Daniel J. DeAngelo, MD, Brian A. Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, MD PhD, Anjali S. Advani, MD, Paula Marlton, Michael E O'Dwyer, MD, William E Fogler, PhD, Curt D Wolfgang, PhD, John L Magnani, PhD, Helen M Thackray, MD, Pamela S. Becker, MD

Blood (2018) 132 (Supplement 1): 331.

https://doi.org/10.1182/blood-2018-99-114286

Published: 2018

Journal Articles

Qualitative Study of Factors That Influence Treatment Decision-Making Among Community Oncologists and Older Patients with Acute Myeloid Leukemia

Kah Poh Loh, MBBCHBAO, Sindhuja Kadambi, MD, Supriya G. Mohile, MD MS, Jason H. Mendler, MD PhD, Jane L. Liesveld, MD, Kristen M. O'Dwyer, MD, Michael W. Becker, MD, Colin M. McHugh, MD, Marsha Wittink, MD MBE, Wendy Stock, MD, Navneet S. Majhail, MD MS, Tanya Wildes, MD, Paul Duberstein, PhD, Heidi D. Klepin, MD MS

Blood (2018) 132 (Supplement 1): 2246.

https://doi.org/10.1182/blood-2018-99-114178

Published: 2018

Journal Articles

Access and Referral Barriers to Autologous and Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Cancer: A Systematic Review with a Specific Focus on Geriatric Population

Kah Poh Loh, MBBCHBAO, Jian Liang Tan, Colin M. McHugh, MD, Jane L. Liesveld, MD, Kristen M. O'Dwyer, MD, Michael W. Becker, MD, Jason H. Mendler, MD PhD, Omar S. Aljitawi, MD, Heidi D. Klepin, MD MS, Wendy Stock, MD, Tanya Wildes, MD, Andrew S Artz, MD, Areej El-Jawahri, MD, Navneet S. Majhail, MD MS

Blood (2018) 132 (Supplement 1): 2245.

https://doi.org/10.1182/blood-2018-99-112320

Published: 2018

Journal Articles

Role of RasGRP3 in EPO/EPOR Signaling and Transmigration of Human Hematopoietic CD34+ Cells

Yahui Grace Chiu, PhD, Jacquelyn Lillis, MS, Rakesh Singh, PhD, Jane L. Liesveld, MD, Laura M. Calvi, MD, John M Ashton, PhD, Omar S. Aljitawi, MD

Blood (2018) 132 (Supplement 1): 4531.

https://doi.org/10.1182/blood-2018-99-116807

Published: 2018

Journal Articles

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Rachel J. Cook, MD, Tamara Moyo, MD PhD, Jane L. Liesveld, MD, David A. Rizzieri, MD, Eytan M. Stein, MD, Stephane De Botton, MD PhD, Gail J. Roboz, MD, Mikkael A. Sekeres, MD MS, Joseph G. Jurcic, MD, Azra Raza, MD, Robert L. Redner, MD, Dale L. Bixby, MD PhD, Jorge E. Cortes, MD, Kristin Stephens, Angela Volkert, Qing Kang, PhD, Emmanuelle Di Tomaso, PhD, David A. Roth, MD, Carlos E Vigil, MD

Blood (2018) 132 (Supplement 1): 2735.

https://doi.org/10.1182/blood-2018-99-111285

Published: 2018

Journal Articles

IQGAP1: A Potential Therapeutic Target in Acute Myelogenous Leukemia (AML)

Deepak Sahasrabudhe, MD, John M Ashton, PhD, Andrew G Evans, MD PhD, McMahon Loralee, Balys Merlene, MS, Jane L. Liesveld, MD

Blood (2017) 130 (Supplement 1): 1391.

https://doi.org/10.1182/blood.V130.Suppl_1.1391.1391

Published: 2017

Journal Articles

GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study

Daniel J. DeAngelo, MD, Brian A Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, Anjali S. Advani, MD, Paula Marlton, MBBS, Michael O'Dwyer, MD, John L Magnani, PhD, Helen M. Thackray, MD, Pamela S. Becker, MD PhD

Blood (2017) 130 (Supplement 1): 894.

https://doi.org/10.1182/blood.V130.Suppl_1.894.894

Published: 2017

NARROW

SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia

Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

Early Completion of Medical Orders for Life-Sustaining Treatment (MOLST) and Hospice Enrollment Are Associated with Improved End of Life (EOL) Quality Metrics in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Treatment Decision-Making and Decisional Support Experiences Among Acute Myeloid Leukemia Survivors

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Older Adults with Acute Myeloid Leukemia (AML)

A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

A Specific Mesenchymal Stem and Progenitor Cell (MSPC) Subpopulation with a Multi-Potent Gene Signature Is Transcriptionally Altered in the Setting of Myelodysplastic Syndrome (MDS) in Primary Human Bone Marrow Aspirates

High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Alliance A041701 - a Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia (AML) Receiving Intensive Induction Chemotherapy

Cancer-Related Distress and Unmet Needs Among Acute Myeloid Leukemia Survivors

Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses

Qualitative Study of Factors That Influence Treatment Decision-Making Among Community Oncologists and Older Patients with Acute Myeloid Leukemia

Access and Referral Barriers to Autologous and Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Cancer: A Systematic Review with a Specific Focus on Geriatric Population

Role of RasGRP3 in EPO/EPOR Signaling and Transmigration of Human Hematopoietic CD34+ Cells

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

IQGAP1: A Potential Therapeutic Target in Acute Myelogenous Leukemia (AML)

GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only